BioSpace News Archive

German vascular integrity specialist Adrenomed AG, announced today that the first patient with early septic shock has been dosed in the ADR-02 Phase-II study conducted in Germany, Belgium, France and the Netherlands.

Members of Integra’s executive leadership team will discuss the company’s financial performance and outlook.

The company reports that it has adopted recommendations from the INTEREST trial’s Independent Data Monitoring Committee and Steering Committee to present patient data showing blinded ARDS outcomes at 90 days.

The primary endpoint of the study, a 10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.

The CMML study is one of four ongoing company-sponsored Phase 2 studies of tipifarnib.

These data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017.

Please note MorphoSys AG’s financial reporting dates 2018 as follows...

Company will publish a separate announcement on new time and date of 3rd quarter webinar.

Kyowa Hakko announced today that the results of the Global Phase 3 study investigating the use of KW-0761 in patients with CTCL will be presented at the Annual Meeting of ASH 2017.

Bioverativ presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis, and improved anemia in six of six severely anemic primary CAgD patients in a Phase 1b clinical trial.